Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 19];8(6):s425. Available from: https://skin.dermsquared.com/skin/article/view/3101